← Browse by Condition
Medical Condition

acute myeloid leukemia

Total Trials
9
Recruiting Now
9
Trial Phases
Phase 2, Phase 1, Phase 3

Leukemia clinical trials cover acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), and chronic lymphocytic leukemia (CLL) — distinct diseases with profoundly different biology and treatment approaches. AML research focuses on targeted agents for FLT3, IDH1/2, and TP53-mutated disease, while CLL trials explore fixed-duration venetoclax combinations that achieve treatment-free remissions.

Active trials investigate menin inhibitors for NPM1/KMT2A AML, magrolimab (anti-CD47) combinations, bispecific antibodies in relapsed ALL, and next-generation BTK inhibitors (pirtobrutinib) for ibrutinib-resistant CLL. MRD (minimal residual disease) negativity is emerging as a regulatory endpoint to accelerate approvals.

Frequently Asked Questions — acute myeloid leukemia Clinical Trials

How many clinical trials are currently recruiting for acute myeloid leukemia?
ClinicalMetric currently tracks 9 actively recruiting clinical trials for acute myeloid leukemia, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 9. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for acute myeloid leukemia?
acute myeloid leukemia research spans Phase 1 (4 trials), Phase 2 (4 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a acute myeloid leukemia clinical trial?
Eligibility criteria for acute myeloid leukemia trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
4
Phase 2
4
Phase 3
1
Top Sponsors
Shenzhen Geno-Immune Medical Institute 2 trials
Ruijin Hospital 1 trial
Bristol-Myers Squibb 1 trial
First Affiliated Hospital of Zhejiang University 1 trial
Fred Hutchinson Cancer Center 1 trial

Recruiting Clinical Trials

NCT07548710 Phase 2
Recruiting

Study of SA+X in the Treatment of Newly Diagnosed AML

Enrollment
205 pts
Location
China
Sponsor
Ruijin Hospital
View Trial →
NCT06073769
Recruiting

A Post-Marketing Surveillance Study to Assess the Safety of Oral Azacitidine Maintenance Therapy in Korean Patients With Acute Myeloid Leukemia

Enrollment
154 pts
Location
South Korea
Sponsor
Bristol-Myers Squibb
View Trial →
NCT05995028 Phase 1
Recruiting

Universal 4SCAR7U Targeting CD7-positive Malignancies

Enrollment
30 pts
Location
China
Sponsor
Shenzhen Geno-Immune Medical I...
View Trial →
NCT06621199 Phase 2
Recruiting

Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AML

Enrollment
42 pts
Location
China
Sponsor
First Affiliated Hospital of Z...
View Trial →
NCT04195633 Phase 2
Recruiting

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Enrollment
60 pts
Location
United States
Sponsor
Fred Hutchinson Cancer Center
View Trial →
NCT06389292 Phase 3
Recruiting

A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia

Enrollment
486 pts
Location
China, Russia
Sponsor
Ascentage Pharma Group Inc.
View Trial →
NCT02390635 Phase 1
Recruiting

PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia

Enrollment
77 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →
NCT03222674 Phase 1, Phase 2
Recruiting

Multi-CAR T Cell Therapy for Acute Myeloid Leukemia

Enrollment
10 pts
Location
China
Sponsor
Shenzhen Geno-Immune Medical I...
View Trial →
NCT06001788 Phase 1
Recruiting

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Enrollment
171 pts
Location
United States, Italy...
Sponsor
Kura Oncology, Inc.
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology